Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
Nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease, is widely expected to be the next big thing in biopharma. Thanks to the out-of-control obesity pandemic and truckloads of research dollars pouring into this space at the moment, NASH drugs are projected to only slightly trail the sum total of all diabetes medications in terms of sales by 2028.
NASH medications, in effect, are expected to balloon into the third-largest pharmaceutical market over the course of the next decade. That's an eye-catching growth projection, given that there are no NASH-specific drugs even on the market right now.
Image source: Getty Images.
Source Fool.com